Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11574020 | 0.98 | — | — | |
| SCHEMBL1504016 | 0.89 | TSHR (0.37) | TSHRALDH1A1MGLLNOTUMPNMT | |
| SCHEMBL27637793 | 0.87 | TSHR (0.35) | TSHRALDH1A1MGLLNOTUMPNMT | |
| Hydrochloric Acid SCHEMBL11203807 | 0.82 | — | — | |
| SCHEMBL2915809 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL31299764 | 0.71 | CA12 (0.50) | TSHRALDH1A1TDP1KMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL10986928 | 0.71 | ACHE (0.50) | TSHRALDH1A1MGLLTDP1SMN1; SMN2 | |
| SCHEMBL826242 | 0.71 | TSHR (0.50) | TSHRALDH1A1CYP3A4HSD17B10TP53 | |
| SCHEMBL31448035 | 0.70 | AR (0.47) | ALDH1A1SMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL9343117 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114874155-A | Benzyl thiazolamine compounds and preparation method and anti-tumor application thereof | 华南理工大学 | 2022-08-09 | — | — | CN | claimed |
| JP-57139146-A | — | — | None | — | — | JP | disclosed |
| CN-114874155-B | Benzyl thiazole amine compound, preparation method and anti-tumor application thereof | 华南理工大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-114874155-A | Benzyl thiazolamine compounds and preparation method and anti-tumor application thereof | 华南理工大学 | 2022-08-09 | — | — | CN | disclosed |
| WO-2017089470-A1 | PROCESS FOR THE SYNTHESIS OF ARYLDIAZONIUM SALTS USING NITROGEN OXIDES IN OXYGEN-CONTAINING GAS STREAMS, ESPECIALLY FROM INDUSTRIAL WASTE GASES | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2017-06-01 | — | — | WO | disclosed |
| EP-3173401-A1 | PROCESS FOR THE SYNTHESIS OF ARYLDIAZONIUM SALTS USING NITROGEN OXIDES IN OXYGEN-CONTAINING GAS STREAMS, ESPECIALLY FROM INDUSTRIAL WASTE GASES | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | AATRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1720860-A1 | TRIAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-15 | — | — | EP | disclosed |
| US-20060019997-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-26 | — | — | US | disclosed |
| US-5468857-A | Phenylmethoxypropenoic esters | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-11-21 | — | — | US | disclosed |
| EP-0307103-B1 | Fungicides | ZENECA LTD (GB) | 1994-09-21 | — | — | EP | disclosed |
| US-5334748-A | A methyl 2-aryl heterofunctional phenoxyphenyl-3-methoxy-propenoate compound; treating the plant diseases | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-08-02 | — | — | US | disclosed |
| CN-1021009-C | FUNGICIDES | ICI PLC (GB) | 1993-06-02 | — | — | CN | disclosed |
| US-4515940-A | REACTING ARYLDIAZONIUM SALTS WITH ALKALI OR ALKALINE EARTH METAL SULFITES | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-05-07 | — | — | US | disclosed |
| EP-0068338-B1 | Process for preparing phenyldiazosulphonates | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-12-12 | — | — | EP | disclosed |
| EP-0068338-A1 | Process for preparing phenyldiazosulphonates | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-01-05 | — | — | EP | disclosed |
| JP-S57139146-A | STABILIZATION OF DIAZONIUM SALT TYPE AZOIC DYE | SHOWA KAKO KK | 1982-08-27 | — | — | JP | disclosed |
| US-4145362-A | DIAZOTIZATION OF ARYLAMINE IN PRESENCE OF ALKANOIC ACID, COPPER HALIDE CATALYST | S.A. P R B EN NEERLANDAIS PRB N.V. (BE) | 1979-03-20 | — | — | US | disclosed |
| US-4046763-A | INTERMEDIATE FOR ULTRAVIOLET LIGHT ABSORBERS | MCNEIL LABORATORIES, INCORPORATED (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | TSHR 1385/4885ALDH1A1 410/4885MGLL 2879/4885 |
| US-20060019997-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRIN3A, GRM1 | TSHR 377/4885ALDH1A1 3228/4885MGLL 4027/4885 |
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRM3, GRIK5 | TSHR 483/4885ALDH1A1 3599/4885MGLL 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.